Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide

CRANFORD, N.J. , Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR ).

"The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR's differentiated clinical profile," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.

"Following the quarter end, we completed the nationwide deployment of Citius Oncology's expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR's success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures," added Mazur.

"We also continued to advance LYMPHIR's longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT ® & CIBMTR ® Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR's potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR," concluded Mazur.

Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments Continued commercial momentum for LYMPHIR, with availability in 44 institutions, including academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions and community infusion centers; Increased the number of new institutions ordering LYMPHIR by 80% and grew institutional vial orders from wholesalers by 31%; Drove continued institutional demand growth in July, with 383 vials ordered by institutions from wholesalers, the largest vial order month to date; Secured near universal payer coverage, with no reimbursement denials or preauthorization barriers reported to date; Expanded Citius Oncology's commercial organization by 21 commercial field-based professionals and added eight medical science liaisons, with nationwide deployment completed in August 2026 through EVERSANA, the Company's exclusive commercialization partner; Advanced Phase 1 investigator-initiated trials: Data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies: 24% overall response rate (ORR) and a 48% clinical benefit rate, and median progression-free survival of 20.5 months among patients achieving clinical benefit;